Tisagenlecleucel, CAS 1823078-37-0

Product Description: Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Bishop MR, et, al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):629-639. /[2]Fowler NH, et, al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 Feb;28(2):325-332.

CAS Number: 1823078-37-0

Molecular Weight: N/A

Research Area: Cancer; Inflammation/Immunology

Solubility: H2O

Target: CD19

• Artikelnummer: MEXHY-P99338-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99338-5
• Green Labware: Nein
• Verpackungseinheit: 5mg
• Mengeneinheit: STK